TITLE

Study Shows Weight Loss Program with Xenical Can Also Help Lower Blood Pressure in Obese Hypertensive Patients

PUB. DATE
November 2000
SOURCE
Ascribe Newswire: Medicine;11/13/2000, p5
SOURCE TYPE
Newswire
DOC. TYPE
Article
ABSTRACT
The article cites a study by researchers at the University of Alabama at Birmingham, Alabama, which holds that weight loss program with xenical can help in lowering blood pressure in obese hypertension patients. Results from a multicoated clinical trial show that weight loss induced by xenical can significantly reduce elevated blood pressure in overweight people. They also found that a greater percentage of patients who received xenical obtained a significant blood pressure benefit by reducing their blood pressure to a normal level or by at least 10 points.
ACCESSION #
11082555

 

Related Articles

  • Orlistat: A Viewpoint by F. Xavier Pi-Sunyer. Pi-Sunyer, F.X. // Drugs;Aug1998, Vol. 56 Issue 2, p250 

    Offers views on the anti-obesity drug orlistat. Mechanism of actio; Toxicity; Effectiveness.

  • Orlistat: A Viewpoint by Madeleine L. Drent. Drent, M.L. // Drugs;Aug1998, Vol. 56 Issue 2, p250 

    Offers views on the anti-obesity drug orlistat. Physiological effects of orlistat; Effectiveness; Adverse effects.

  • Orlistat. McNeely, W.; Benfield, P. // Drugs;Aug1998, Vol. 56 Issue 2, p241 

    â–´ Orlistat (tetrahydrolipstatin) is an inhibitor of pancreatic and other lipases. As a pancreatic lipase inhibitor, it acts in the gastrointestinal lumen and is indicated for use in obesity. â–´ Serum total cholesterol and low density lipoprotein-cholesterol levels were reduced in...

  • Orlistat.  // Reactions Weekly;9/17/2011, Issue 1369, p30 

    The article describes the case of a woman who developed a lichenoid drug eruption (LDE) following treatment with orlistat for obesity.

  • Market impact remains unclear as pending switches head to stores. Johnsen, Michael // Drug Store News;1/17/2005, Vol. 27 Issue 1, p34 

    Reports on the increasing category sales among blockbuster drug switches in the U.S. Introduction of a new nonprescription alternative for the diet aid set in 2006; Amendment of switch application for the emergency contraceptive plan B; Plan of GlaxoSmithKline to file a switch application for...

  • Safety profile of orlistat: results of a prescription-event monitoring study. Acharya, N. V.; Wilton, L. V.; Shakir, S. A. W. // International Journal of Obesity;Nov2006, Vol. 30 Issue 11, p1645 

    Introduction:Orlistat, the first of a new class of drugs for the treatment of obesity, was launched in the UK in December 1998. The prescribing information recommends that treatment with orlistat should be discontinued after 12 weeks if the patient has not achieved a specified loss of...

  • Press coverage and sales of Xenical in Sweden, 1998—2000. Brounéus, Fredrik; Dahlin, Anna; Beermann, Björn // European Journal of Clinical Pharmacology;Jun2005, Vol. 61 Issue 4, p285 

    Objective: The anti-obesity drug Xenical (orlistat, Roche) was launched on the Swedish market in February 1999. The sales peaked in May 1999 and then declined. The purpose of this study was to investigate the press coverage of Xenical during the period 1998–2000 and, if possible, relate...

  • Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report. Theleritis, Christos G.; Papadimitriou, George N.; Papageorgiou, Charalabos C.; Dikeos, Dimitris G.; Masdrakis, Vasilis; Kostoulas, Constantin; Psarros, Constantin; Soldatos, Constantin R. // BMC Psychiatry;2006, Vol. 6, p37 

    Background: The use of atypical antipsychotics in schizophrenic patients has been associated with a risk of weight gain. Similarly, recovery from depression is often followed by improved appetite, greater food intake and potential increase in weight. Case presentation: A Caucasian 33-year-old...

  • Supplier News.  // Drug Store News;5/2/2005, Vol. 27 Issue 6, p41 

    The article reports that GlaxoSmithKline PLC has agreed to promote Roche Inc.'s prescription weight-loss drug Xenical or orlistat to physicians in the U.S. just months before GlaxoSmithKline plans to file an application to switch orlistat to over-the-counter status with a different dosing...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics